Our team has extensive experience in the medical device and biosensor industries.
Executive Management
Jaiho Cho
Chief Executive Officer
Jake was appointed as the Chief Executive Officer of AgaMatrix in 2023. He has over 25 years of experience in cross-border M&A, capital markets, and financial derivatives. Jake is a seasoned healthcare and bio-M&A professional with a strong track record of deal sourcing, execution, and post-merger integration. He focuses on pre-IPO assets in the MedTech and broader healthcare industry. Jake is a Columbia Law School graduate and a former credit analyst. He has a rigorous analytical approach to problem-solving and a passion for innovation and excellence. Jake is also a board member of CoaguSense, a company that develops and markets a novel blood coagulation monitoring system. He is driven by the mission of improving the lives of people with chronic conditions through cutting-edge technology and personalized care.
Cara Mottolo
Vice President of Human Resources & Administration
Cara has been the leader of all People Operations activities at AgaMatrix since late 2010 and continues in this role. She also manages due diligence efforts and ensures Corporate Communication reflects the company accurately. For the last two years, she has overseen and advised the G&A functions of the company and acted as the main liaison for the company’s shareholders and employees on equity administration. Cara has nineteen years of experience in the Human Resources profession and has worked in various industries from the medical device company NMT Medical, Inc. to the sports and entertainment venue the Boston Garden (formerly the FleetCenter). In the early stages of her professional career, Cara was in Broadcast Journalism with on-air roles at several local radio stations. Cara has a B.A. in Communications from the University of Massachusetts, Amherst.
Chuck Johnson
Vice President of Engineering
With almost 40 years of engineering experience, Chuck is a seasoned technical manager. He came to AgaMatrix in 2011 and has been leading the company’s engineering development activities as a senior leader. Chuck has played a vital role in the company’s product portfolio, from the first iPhone-compatible blood glucose monitor that got FDA clearance, iBGStar, to the latest Jazz Wireless 2 glucose monitor with Bluetooth. Chuck has also held several successful positions in the medical device industry, such as the Director of Engineering at Eleme Medical (bought by Cynosure), where he managed the development of systems for treating various conditions, such as kidney stones, vascular lesions, wrinkles, cellulite, tattoo removal, and hair removal. He was also Vice President, Development Engineering at Candela Corporation, where he oversaw the development of the company’s variable pulse duration YAG Laser for hair removal, which was the company’s most profitable product. Chuck obtained his Master’s degree in Electrical Engineering from Worcester Polytechnic Institute and his Bachelor’s in Electrical Engineering from Manhattan College.
David Olsen
Vice President of Quality Assurance, Regulatory and Clinical Affairs
Dave came to AgaMatrix with 25 years of experience as a Regulatory Affairs & Quality professional in the fields of IVD, Medical Devices, Biotechnology and Biologics. He has a lot of experience in new product development and licensing in the U.S., Canada, European Union, Brazil, India and China. Before joining AgaMatrix, he was the Director of Regulatory Affairs, Clinical Affairs and Quality Assurance at Harvard Apparatus Regenerative Technology, Inc., a biotechnology company in Holliston, MA that focuses on developing cell-based tracheal prostatic. He also worked as the Vice President, Corporate Regulatory & Quality for 5 years at SeraCare Life Sciences, Inc., a $60M IVD Biotechnology Company that makes serological and nucleic acid controls and reference materials. Dave had executive and management roles at Defibtech, LLC, American Red Cross, and C.R. Bard, Inc. before that. David has a JD from the Massachusetts School of Law, a BS in Chemistry from Salem State University, and an LL.M. in Banking and Financial Law at Boston University School of Law.
Board of Directors
Chandra Selvadurai
Chairman
Chandra Selvadurai is a seasoned professional with over 25 years of experience in the healthcare industry. He has a strong background in international pharma and medtech businesses, including business development, sales, management, and commercial excellence. Chandra has led and developed cross-functional teams in a matrix environment and has proven marketing skills with a focus on growth, agility, and innovation. He has deep knowledge and experience in regulatory affairs across Asia Pacific markets (APAC) and has a strategic thinking combined with a tactical approach to drive business results. Chandra is recognized for his strong team motivation, collaboration, and communication skills at all levels of the organization and within multicultural teams. Chandra is currently the Managing Director of Pharmaco NZ and Australia Ltd where he has been working since July 1994. He has held various positions in the company, including Sales and Marketing Manager, co-CEO, CEO, and Managing Director. In his current role, he has been leading the trans-Tasman operations of Pharmaco, a company specializing in the sales, marketing, warehousing, and distribution of medical devices, pharmaceuticals, and healthcare products and services. The company started in 1967, is New Zealand-owned, and entered the Australian market in 2003. It currently manages over 2,500 products on behalf of international organizations, supported by best-practice regulatory, compliance, quality assurance, customer support, and finance and administration services.
Dr. Hakhyun Nam
Director
Dr. Hakhyun Nam is the CEO of i-SENS, a global leader in the development of glucose sensor devices. He has a Bachelor of Science degree from Seoul National University and a Master’s and PhD from Michigan State University, all in the field of Chemistry. Dr. Nam has over 25 years of experience in the healthcare industry, including a 23-year tenure as a Professor of Chemistry at Kwangwoon University. He is currently an Emeritus Professor at Kwangwoon University and has been the CEO of i-SENS since 2020. Dr. Nam has been with i-SENS since 2000, where he started as the Chief Technology Officer (CTO). He has been instrumental in the company’s success and has helped establish its reputation within the Korean market. Under his leadership, i-SENS has won several awards, including the Health and Medical Science and Technology Research and Development Excellence Award in 2008 and the Citation of Merit Award for Industrial-education Cooperation and Citation of Merit Award for Industrial Technology in 2011.
Jaiho Cho
Chief Executive Officer and Director
Jake was appointed as the Chief Executive Officer of AgaMatrix in 2023. He has over 25 years of experience in cross-border M&A, capital markets, and financial derivatives. Jake is a seasoned healthcare and bio-M&A professional with a strong track record of deal sourcing, execution, and post-merger integration. He focuses on pre-IPO assets in the MedTech and broader healthcare industry. Jake is a Columbia Law School graduate and a former credit analyst. He has a rigorous analytical approach to problem-solving and a passion for innovation and excellence. Jake is also a board member of CoaguSense, a company that develops and markets a novel blood coagulation monitoring system. He is driven by the mission of improving the lives of people with chronic conditions through cutting-edge technology and personalized care.
Our proprietary science and designs are protected by 170 granted and 39 pending U.S. and international patents.